BioCardia Revenue and Competitors
Estimated Revenue & Valuation
- BioCardia's estimated annual revenue is currently $7.5M per year.
- BioCardia's estimated revenue per employee is $241,935
- BioCardia's total funding is $7.4M.
Employee Data
- BioCardia has 31 Employees.
- BioCardia grew their employee count by -6% last year.
BioCardia's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Sr. VP Devices | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | VP, Development | Reveal Email/Phone |
5 | VP Clinical Research | Reveal Email/Phone |
6 | Associate Director Physician Relations | Reveal Email/Phone |
7 | Director Regulatory Affairs | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Associate Director Quality Engineering and Compliance | Reveal Email/Phone |
10 | Managing Director | Reveal Email/Phone |
BioCardia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is BioCardia?
BioCardia is developing platform technologies and products for improving cardiac care. BioCardia's mission is to enable delivery of drugs to the sites where they are most needed, reduce the amount of drug required, increase the therapeutic index, and control the time course of agent delivery. BioCardia's products include intramyocardial catheter delivery systems and local controlled release technologies.
keywords:N/A
$7.4M
Total Funding
31
Number of Employees
$7.5M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BioCardia News
Zacks: Brokerages Expect BioCardia, Inc. (NASDAQ:BCDA) Will Post Quarterly Sales of $190,000.00. Posted by admin on Apr 24th, 2022.
BioCardia chief scientific officer Ian McNiece said: This investigational cell therapy is administered intravenously (IV) and follows a...
This allows BioCardia to initiate its First-in-Human Phase I/II trial in adult patients recovering from Acute Respiratory Distress Syndrome (...
Other Companies in San Carlos
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.2M | 32 | -9% | N/A |
#2 | $7.1M | 33 | 6% | N/A |
#3 | N/A | 34 | 62% | N/A |
#4 | $5.9M | 35 | -5% | N/A |
#5 | $2.8M | 35 | -30% | N/A |